{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T22:27:46Z","timestamp":1787783266338,"version":"build-2784847793"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-02868-7","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T13:02:36Z","timestamp":1714050156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world setting"],"prefix":"10.1007","volume":"316","author":[{"given":"Natalia","family":"Rompoti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Stefanaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantelis","family":"Panagakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charitomeni","family":"Vavouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Politou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Papoutsaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aggeliki","family":"Befon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiori","family":"Koutsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Lazou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis-Alexios","family":"Koumprentziotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Chasapi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Stratigos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Electra","family":"Nicolaidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"2868_CR1","doi-asserted-by":"publisher","unstructured":"Reich K, Papp KA, Blauvelt A et al (2021) Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial [published correction appears in Lancet. ;397(10275):670]. Lancet. 2021;397(10273):487\u2013498. https:\/\/doi.org\/10.1016\/S0140-6736(21)00125-2","DOI":"10.1016\/S0140-6736(21)00125-2"},{"key":"2868_CR2","doi-asserted-by":"publisher","unstructured":"Gordon KB, Foley P, Krueger JG et al (2021) Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial [published correction appears in Lancet. ;397(10280):1182]. Lancet. 2021;397(10273):475\u2013486. https:\/\/doi.org\/10.1016\/S0140-6736(21)00126-4","DOI":"10.1016\/S0140-6736(21)00126-4"},{"issue":"2","key":"2868_CR3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa2102388","volume":"385","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Bagel J et al (2021) Bimekizumab versus Adalimumab in Plaque Psoriasis. N Engl J Med 385(2):130\u2013141. https:\/\/doi.org\/10.1056\/NEJMoa2102388","journal-title":"N Engl J Med"},{"key":"2868_CR4","doi-asserted-by":"publisher","unstructured":"Gordon KB, Langley RG, Warren RB et al (2023) Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled data from up to three years of treatment in randomized phase 3 trials. Br J Dermatol Published Online November 10. https:\/\/doi.org\/10.1093\/bjd\/ljad429","DOI":"10.1093\/bjd\/ljad429"},{"key":"2868_CR5","doi-asserted-by":"publisher","first-page":"1243843","DOI":"10.3389\/fmed.2023.1243843","volume":"10","author":"L Gargiulo","year":"2023","unstructured":"Gargiulo L, Narcisi A, Ibba L et al (2023) Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis). Front Med (Lausanne) 10:1243843 Published 2023 Aug 8. https:\/\/doi.org\/10.3389\/fmed.2023.1243843","journal-title":"Front Med (Lausanne)"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-02868-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-02868-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-02868-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T09:47:02Z","timestamp":1717494422000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-02868-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":5,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["2868"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-02868-7","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]},"assertion":[{"value":"21 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"- N. Rompoti: Honoraria for lectures from AbbVie, Genesis Pharma, Janssen, LEO, Lilly Pharmaserve, Novartis, UCB and support for scientific congress attendance from AbbVie, Janssen, LEO, Lilly Pharmaserve, Novartis, UCB.- I. Stefanaki: Honoraria from AbbVie, Genesis, Janssen, LEO Pharma and Novartis.- P. Panagakis: Honoraria for advisory boards, lectures, and support for travelling to scientific meetings from Abbvie, LEO Pharma, Janssen, Genesis Pharma, Novartis, MyLan, Lilly, Pfizer, UCB- M. Papoutsaki: Honoraria for advisory boards and lectures from Janssen, LEO Pharma, MSD, Genesis Pharma, Pfizer, Novartis, AbbVie, UCB, and support as investigator in clinical studies from AbbVie, Novartis, LEO Pharma, Janssen.- M. Politou: Honoraria for advisory boards from AbbVie, Novartis, Genesis, LEO Pharma, honoraria for lectures from AbbVie, Janssen, Novartis, Genesis, UCB, LEO Pharma. - C. Vavouli: Honoraria for advisory boards from LEO Pharma, Galenica, honoraria for lectures from LEO Pharma, Genesis, Novartis, and support for congress attendance from LEO Pharma, Genesis, Novartis, and Janssen.- A. Befon: No conflict of interest- \tF. Kousta: No conflict of interest- E. Lazou: No conflict of interest- I.-A. Koumprentziotis: No conflict of interest- V. Chasapi: Honoraria for lectures, and support for travelling to scientific meetings from Abbvie, Genesis Pharma, Janssen, LEO Pharma, Novartis- A. Stratigos: Honoraria for advisory boards, lectures, and support for international congress attendance from Bristol-Myers Squibb, Novartis, Merck Sharp & Dohme, Sanofi, and research support from Hoffmann-La Roche.- E. Nicolaidou: Honoraria for advisory board, lectures, and support for scientific meeting attendance from Janssen, LEO Pharma, Novartis, UCB, Lilly Pharmaserve, Gelgene\/Genesis Pharma, Galenica, Amgen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}